Relevant bibliographies by topics / Cancer immunotherapies / Journal articles

Journal articles on the topic 'Cancer immunotherapies'

To see the other types of publications on this topic, follow the link: Cancer immunotherapies.
Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer immunotherapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bergman, Philip J. "Cancer Immunotherapies." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): 881–902. http://dx.doi.org/10.1016/j.cvsm.2019.04.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

DAVIS, Ian D., and Jonathan S. CEBON. "Developing cancer immunotherapies." Asia-Pacific Journal of Clinical Oncology 7 (March 24, 2011): 9–13. http://dx.doi.org/10.1111/j.1743-7563.2011.01382.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ott, Patrick A. "Intralesional Cancer Immunotherapies." Hematology/Oncology Clinics of North America 33, no. 2 (April 2019): 249–60. http://dx.doi.org/10.1016/j.hoc.2018.12.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Immunotherapies for cancer reviewed." Inpharma Weekly &NA;, no. 1432-1433 (April 2004): 2. http://dx.doi.org/10.2165/00128413-200414320-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gubens, Matthew A. "Immunotherapies for Lung Cancer." Journal of the National Comprehensive Cancer Network 15, no. 5S (May 2017): 692–95. http://dx.doi.org/10.6004/jnccn.2017.0075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fakhrejahani, Farhad, Yusuke Tomita, Agnes Maj-Hes, Jane B. Trepel, Maria De Santis, and Andrea B. Apolo. "Immunotherapies for bladder cancer." Current Opinion in Urology 25, no. 6 (November 2015): 586–96. http://dx.doi.org/10.1097/mou.0000000000000213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Berraondo, Pedro, Sara Labiano, Luna Minute, Iñaki Etxeberria, Marcos Vasquez, Alvaro Sanchez-Arraez, Alvaro Teijeira, and Ignacio Melero. "Cellular immunotherapies for cancer." OncoImmunology 6, no. 5 (May 2, 2017): e1306619. http://dx.doi.org/10.1080/2162402x.2017.1306619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mulé, James J., and Jeffrey S. Weber. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1153. http://dx.doi.org/10.1038/nm1104-1153a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pardoll, Drew, and James Allison. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1153–54. http://dx.doi.org/10.1038/nm1104-1153b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Skipper, Jonathan, Eric W. Hoffman, Jill O'Donnell-Tormey, and Lloyd J. Old. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1154–55. http://dx.doi.org/10.1038/nm1104-1154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Pardoll, Drew, and James Allison. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1155. http://dx.doi.org/10.1038/nm1104-1155a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

García-Martínez, Elena, and J. Alejandro Pérez-Fidalgo. "Immunotherapies in ovarian cancer." European Journal of Cancer Supplements 15 (August 2020): 87–95. http://dx.doi.org/10.1016/j.ejcsup.2020.02.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Roy, Ruchi, Sunil Kumar Singh, and Sweta Misra. "Advancements in Cancer Immunotherapies." Vaccines 11, no. 1 (December 27, 2022): 59. http://dx.doi.org/10.3390/vaccines11010059.

Full text
Abstract:
Recent work has suggested involvement of the immune system in biological therapies specifically targeting tumor microenvironment. Substantial advancement in the treatment of malignant tumors utilizing immune cells, most importantly T cells that play a key role in cell-mediated immunity, have led to success in clinical trials. Therefore, this article focuses on the therapeutic approaches and developmental strategies to treat cancer. This review emphasizes the immunomodulatory response, the involvement of key tumor-infiltrating cells, the mechanistic aspects, and prognostic biomarkers. We also cover recent advancements in therapeutic strategies.
APA, Harvard, Vancouver, ISO, and other styles
14

Saly, Danielle L., and Mark A. Perazella. "The adverse kidney effects of cancer immunotherapies." Journal of Onco-Nephrology 2, no. 2-3 (June 2018): 56–68. http://dx.doi.org/10.1177/2399369318808806.

Full text
Abstract:
Cancer therapies are a common cause of acute and chronic kidney disease, which are increasingly being seen by nephrologists in clinical practice. Conventional chemotherapeutic drugs and novel targeted agents are effective cancer therapies but their use is complicated by nephrotoxicity. Cancer immunotherapies exploit various properties of immune cells to enhance immune-mediated tumor killing. Interferon and high-dose interleukin-2 are older immunotherapies first employed clinically in the 1980s and 1990s to treat a number of different cancers. While effective, these two therapies have well-known systemic toxicities, which include acute kidney disease. The emergence of the new cancer immunotherapies over the past decade brings more effective treatment options. The immune checkpoint inhibitors and chimeric antigen receptor T cells are exciting additions to the cancer treatment armamentarium. These agents effectively treat a several and a growing list of cancers that have otherwise failed other therapies. However, as with the conventional and targeted cancer agents, drug-induced acute and chronic kidney disease is an untoward effect of this group of drugs. We will undertake a case-based review: the newer immunotherapies followed by the older therapies, interferon and interleukin-2.
APA, Harvard, Vancouver, ISO, and other styles
15

Yi, Qing. "Novel Immunotherapies." Cancer Journal 15, no. 6 (November 2009): 502–10. http://dx.doi.org/10.1097/ppo.0b013e3181c51f0d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Slaney, Clare Y., and Michael H. Kershaw. "Challenges and Opportunities for Effective Cancer Immunotherapies." Cancers 12, no. 11 (October 28, 2020): 3164. http://dx.doi.org/10.3390/cancers12113164.

Full text
Abstract:
Using immunotherapy to treat cancers can be traced back to the 1890s, where a New York physician William Coley used heat-killed bacteria to treat cancer patients, which became known as “Coley’s toxin” [...]
APA, Harvard, Vancouver, ISO, and other styles
17

Platten, Michael, and David Reardon. "Concepts for Immunotherapies in Gliomas." Seminars in Neurology 38, no. 01 (February 2018): 062–72. http://dx.doi.org/10.1055/s-0037-1620274.

Full text
Abstract:
Strategies to empower the immune system to successfully attack cancers, including vaccination approaches, adaptive T cell therapies, and immune checkpoint modulators, have recently achieved remarkable success across a spectrum of cancer indications. Nonetheless, with rare exception, only a minority of patients with a given type of cancer respond to an immunotherapeutic when administered as single-agent therapy. Although under extensive laboratory and clinical investigation, the role of these approaches for glioma patients remains to be determined. While the central nervous system (CNS) is no longer regarded as an immunoprivileged sanctuary, nuances regarding immune responses in the CNS may impact on the activity of immunotherapy treatments of brain tumor patients. Furthermore, many common CNS tumors such as World Health Organization grade III and IV (high grade) gliomas utilize myriad, nonoverlapping strategies to dampen or extinguish antitumor immune responses. For these reasons, critical research efforts are focused on identifying biomarkers that predict patients with a heightened likelihood of therapeutic benefit as well as evaluating rationally designed combinatorial immunotherapy approaches with potentially complementary mechanisms of immune-activation for brain cancer patients.
APA, Harvard, Vancouver, ISO, and other styles
18

Swatler, Julian, and Ewa Kozłowska. "Immune checkpoint‑targeted cancer immunotherapies." Postępy Higieny i Medycyny Doświadczalnej 70 (January 26, 2016): 25–42. http://dx.doi.org/10.5604/17322693.1192926.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Negrini, Simone, Raffaele De Palma, and Gilberto Filaci. "Anti-Cancer Immunotherapies Targeting Telomerase." Cancers 12, no. 8 (August 12, 2020): 2260. http://dx.doi.org/10.3390/cancers12082260.

Full text
Abstract:
Telomerase is a reverse transcriptase that maintains telomeres length, compensating for the attrition of chromosomal ends that occurs during each replication cycle. Telomerase is expressed in germ cells and stem cells, whereas it is virtually undetectable in adult somatic cells. On the other hand, telomerase is broadly expressed in the majority of human tumors playing a crucial role in the replicative behavior and immortality of cancer cells. Several studies have demonstrated that telomerase-derived peptides are able to bind to HLA (human leukocyte antigen) class I and class II molecules and effectively activate both CD8+ and CD4+ T cells subsets. Due to its broad and selective expression in cancer cells and its significant immunogenicity, telomerase is considered an ideal universal tumor-associated antigen, and consequently, a very attractive target for anti-cancer immunotherapy. To date, different telomerase targeting immunotherapies have been studied in pre-clinical and clinical settings, these approaches include peptide vaccination and cell-based vaccination. The objective of this review paper is to discuss the role of human telomerase in cancer immunotherapy analyzing recent developments and future perspectives in this field.
APA, Harvard, Vancouver, ISO, and other styles
20

Basler, Michael, and Marcus Groettrup. "Advances in Prostate Cancer Immunotherapies." Drugs & Aging 24, no. 3 (2007): 197–221. http://dx.doi.org/10.2165/00002512-200724030-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Capsomidis, Anna, and John Anderson. "Developing immunotherapies for childhood cancer." Archives of disease in childhood - Education & practice edition 102, no. 3 (September 29, 2016): 162–65. http://dx.doi.org/10.1136/archdischild-2016-311284.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Kim, Joseph W., Yusuke Tomita, Jane Trepel, and Andrea B. Apolo. "Emerging immunotherapies for bladder cancer." Current Opinion in Oncology 27, no. 3 (May 2015): 191–200. http://dx.doi.org/10.1097/cco.0000000000000177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Weller, M. "Neurologic complications of cancer immunotherapies." Journal of the Neurological Sciences 405 (October 2019): 46–47. http://dx.doi.org/10.1016/j.jns.2019.10.130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Willis, M. D., and N. P. Robertson. "Neurotoxicity of novel cancer immunotherapies." Journal of Neurology 266, no. 8 (June 28, 2019): 2087–89. http://dx.doi.org/10.1007/s00415-019-09444-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

McNeel, Douglas G. "Cellular immunotherapies for prostate cancer." Biomedicine & Pharmacotherapy 61, no. 6 (July 2007): 315–22. http://dx.doi.org/10.1016/j.biopha.2006.12.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Marmé, Dieter. "Advances in Cancer Therapy: Immunotherapies." Oncology Research and Treatment 39, no. 6 (2016): 324–25. http://dx.doi.org/10.1159/000446635.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Scheetz, Lindsay, Kyung Soo Park, Qiao Li, Pedro R. Lowenstein, Maria G. Castro, Anna Schwendeman, and James J. Moon. "Engineering patient-specific cancer immunotherapies." Nature Biomedical Engineering 3, no. 10 (August 12, 2019): 768–82. http://dx.doi.org/10.1038/s41551-019-0436-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Tanaka, Tomokazu, Jun Nakamura, and Hirokazu Noshiro. "Promising immunotherapies for esophageal cancer." Expert Opinion on Biological Therapy 17, no. 6 (April 11, 2017): 723–33. http://dx.doi.org/10.1080/14712598.2017.1315404.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Lou, Kai-Jye. "Viral boost for cancer immunotherapies." Science-Business eXchange 4, no. 26 (June 2011): 728. http://dx.doi.org/10.1038/scibx.2011.728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Fujii, Shin-ichiro, Takuya Takayama, Miki Asakura, Kaori Aki, Koji Fujimoto, and Kanako Shimizu. "Dendritic cell-based cancer immunotherapies." Archivum Immunologiae et Therapiae Experimentalis 57, no. 3 (May 29, 2009): 189–98. http://dx.doi.org/10.1007/s00005-009-0025-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Nishi, Tatsuya, and Yosuke Togashi. "Translational Research in Cancer Immunotherapies." Haigan 62, no. 5 (October 20, 2022): 363–70. http://dx.doi.org/10.2482/haigan.62.363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Milling, Lauren, Yuan Zhang, and Darrell J. Irvine. "Delivering safer immunotherapies for cancer." Advanced Drug Delivery Reviews 114 (May 2017): 79–101. http://dx.doi.org/10.1016/j.addr.2017.05.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Lou, Jenny, Li Zhang, and Gang Zheng. "Advancing Cancer Immunotherapies with Nanotechnology." Advanced Therapeutics 2, no. 4 (January 30, 2019): 1800128. http://dx.doi.org/10.1002/adtp.201800128.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Offidani, Massimo, and Maria Teresa Petrucci. "Introduction to “Immunotherapies for Multiple Myeloma”." Pharmaceuticals 13, no. 11 (November 17, 2020): 396. http://dx.doi.org/10.3390/ph13110396.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Kumar, Vijay, Caitlin Bauer, and John H. Stewart Iv. "Chasing Uterine Cancer with NK Cell-Based Immunotherapies." Future Pharmacology 2, no. 4 (December 9, 2022): 642–59. http://dx.doi.org/10.3390/futurepharmacol2040039.

Full text
Abstract:
Gynecological cancers, including endometrial adenocarcinoma, significantly contribute to cancer incidence and mortality worldwide. The immune system plays a significant role in endometrial cancer pathogenesis. NK cells, a component of innate immunity, are among the critical innate immune cells in the uterus crucial in menstruation, embryonic development, and fighting infections. NK cell number and function influence endometrial cancer development and progression. Hence, it becomes crucial to understand the role of local (uterine) NK cells in uterine cancer. Uterine NK (uNK) cells behave differently than their peripheral counterparts; for example, uNK cells are more regulated by sex hormones than peripheral NK cells. A deeper understanding of NK cells in uterine cancer may facilitate the development of NK cell-targeted therapies. This review synthesizes current knowledge on the uterine immune microenvironment and NK cell-targeted uterine cancer therapeutics.
APA, Harvard, Vancouver, ISO, and other styles
36

Barbari, Cody, Tyler Fontaine, Priyanka Parajuli, Narottam Lamichhane, Silvia Jakubski, Purushottam Lamichhane, and Rahul R. Deshmukh. "Immunotherapies and Combination Strategies for Immuno-Oncology." International Journal of Molecular Sciences 21, no. 14 (July 15, 2020): 5009. http://dx.doi.org/10.3390/ijms21145009.

Full text
Abstract:
The advent of novel immunotherapies in the treatment of cancers has dramatically changed the landscape of the oncology field. Recent developments in checkpoint inhibition therapies, tumor-infiltrating lymphocyte therapies, chimeric antigen receptor T cell therapies, and cancer vaccines have shown immense promise for significant advancements in cancer treatments. Immunotherapies act on distinct steps of immune response to augment the body’s natural ability to recognize, target, and destroy cancerous cells. Combination treatments with immunotherapies and other modalities intend to activate immune response, decrease immunosuppression, and target signaling and resistance pathways to offer a more durable, long-lasting treatment compared to traditional therapies and immunotherapies as monotherapies for cancers. This review aims to briefly describe the rationale, mechanisms of action, and clinical efficacy of common immunotherapies and highlight promising combination strategies currently approved or under clinical development. Additionally, we will discuss the benefits and limitations of these immunotherapy approaches as monotherapies as well as in combination with other treatments.
APA, Harvard, Vancouver, ISO, and other styles
37

Cunningham, Nicholas, Réjean Lapointe, and Sophie Lerouge. "Biomaterials for enhanced immunotherapy." APL Bioengineering 6, no. 4 (December 1, 2022): 041502. http://dx.doi.org/10.1063/5.0125692.

Full text
Abstract:
Cancer immunotherapies have revolutionized the treatment of numerous cancers, with exciting results often superior to conventional treatments, such as surgery and chemotherapy. Despite this success, limitations such as limited treatment persistence and toxic side effects remain to be addressed to further improve treatment efficacy. Biomaterials offer numerous advantages in the concentration, localization and controlled release of drugs, cancer antigens, and immune cells in order to improve the efficacy of these immunotherapies. This review summarizes and highlights the most recent advances in the use of biomaterials for immunotherapies including drug delivery and cancer vaccines, with a particular focus on biomaterials for immune cell delivery.
APA, Harvard, Vancouver, ISO, and other styles
38

Galsky, Matthew D., Arjun V. Balar, Peter C. Black, Matthew T. Campbell, Gail S. Dykstra, Petros Grivas, Shilpa Gupta, et al. "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer." Journal for ImmunoTherapy of Cancer 9, no. 7 (July 2021): e002552. http://dx.doi.org/10.1136/jitc-2021-002552.

Full text
Abstract:
A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.
APA, Harvard, Vancouver, ISO, and other styles
39

Koury, Jeffrey, Mariana Lucero, Caleb Cato, Lawrence Chang, Joseph Geiger, Denise Henry, Jennifer Hernandez, et al. "Immunotherapies: Exploiting the Immune System for Cancer Treatment." Journal of Immunology Research 2018 (2018): 1–16. http://dx.doi.org/10.1155/2018/9585614.

Full text
Abstract:
Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers.
APA, Harvard, Vancouver, ISO, and other styles
40

Zhang, Yangyi, Bethany K. Campbell, Stanley S. Stylli, Niall M. Corcoran, and Christopher M. Hovens. "The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention." Uro 2, no. 2 (April 10, 2022): 74–92. http://dx.doi.org/10.3390/uro2020010.

Full text
Abstract:
Advanced prostate cancers have a poor survival rate and a lack of effective treatment options. In order to broaden the available treatments, immunotherapies have been investigated. These include cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cells and bispecific antibodies. In addition, combinations of different immunotherapies and with standard therapy have been explored. Despite the success of the Sipuleucel-T vaccine in the metastatic, castrate-resistant prostate cancer setting, other immunotherapies have not shown the same efficacy in this population at large. Some individual patients, however, have shown remarkable responsiveness to these therapies. Therefore, work is underway to identify which populations will respond positively to therapy via the identification of predictive biomarkers. These include biomarkers of the immunologically active tumour microenvironment and biomarkers indicative of high neoantigen expression in the tumour. This review examines the constitution of the prostate tumour immune microenvironment, explores the effectiveness of immunotherapies, and finally investigates how therapy selection can be optimised by the use of biomarkers.
APA, Harvard, Vancouver, ISO, and other styles
41

Mandrup, Ole A., and Kenneth A. Howard. "Bioengineered solutions to improve cancer immunotherapies." Therapeutic Delivery 12, no. 5 (May 2021): 339–41. http://dx.doi.org/10.4155/tde-2021-0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Janssen, Eline, Beatriz Subtil, Fàtima de la Jara Ortiz, Henk M. W. Verheul, and Daniele V. F. Tauriello. "Combinatorial Immunotherapies for Metastatic Colorectal Cancer." Cancers 12, no. 7 (July 12, 2020): 1875. http://dx.doi.org/10.3390/cancers12071875.

Full text
Abstract:
Colorectal cancer (CRC) is one of the most frequent and deadly forms of cancer. About half of patients are affected by metastasis, with the cancer spreading to e.g., liver, lungs or the peritoneum. The majority of these patients cannot be cured despite steady advances in treatment options. Immunotherapies are currently not widely applicable for this disease, yet show potential in preclinical models and clinical translation. The tumour microenvironment (TME) has emerged as a key factor in CRC metastasis, including by means of immune evasion—forming a major barrier to effective immuno-oncology. Several approaches are in development that aim to overcome the immunosuppressive environment and boost anti-tumour immunity. Among them are vaccination strategies, cellular transplantation therapies, and targeted treatments. Given the complexity of the system, we argue for rational design of combinatorial therapies and consider the implications of precision medicine in this context.
APA, Harvard, Vancouver, ISO, and other styles
43

Pruitt, Amy. "Complications of cancer therapies including immunotherapies." Journal of the Neurological Sciences 429 (October 2021): 118016. http://dx.doi.org/10.1016/j.jns.2021.118016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Barrero, Maria. "Epigenetic Strategies to Boost Cancer Immunotherapies." International Journal of Molecular Sciences 18, no. 6 (May 23, 2017): 1108. http://dx.doi.org/10.3390/ijms18061108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Walker, Anthony, and Robert Johnson. "Commercialization of cellular immunotherapies for cancer." Biochemical Society Transactions 44, no. 2 (April 11, 2016): 329–32. http://dx.doi.org/10.1042/bst20150240.

Full text
Abstract:
Successful commercialization of a cell therapy requires more than proving safety and efficacy to the regulators. The inherent complexity of cellular products delivers particular manufacturing, logistical and reimbursement hurdles that threaten commercial viability for any therapy with a less than spectacular clinical profile that truly changes the standard of care. This is particularly acute for autologous cell therapies where patients receive bespoke treatments manufactured from a sample of their own cells and where economies of scale, which play an important role in containing the production costs for small molecule and antibody therapeutics, are highly limited. Nevertheless, the promise of ‘game-changing’ efficacy, as exemplified by very high levels of complete responses in refractory haematological malignancies, has attracted capital investments on a vast scale, and the attendant pace of technology development provides promising indicators for future clinical and commercial success.
APA, Harvard, Vancouver, ISO, and other styles
46

Villa, Natalie M., Abtin Farahmand, Lin Du, Michael W. Yeh, Stephanie Smooke-Praw, Antoni Ribas, Bartosz Chmielowski, Grace Cherry, and Angela M. Leung. "Endocrinopathies with use of cancer immunotherapies." Clinical Endocrinology 88, no. 2 (October 9, 2017): 327–32. http://dx.doi.org/10.1111/cen.13483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

HENDERSON, R., S. MOSSMAN, N. NAIRN, and M. CHEEVER. "Cancer vaccines and immunotherapies: emerging perspectives." Vaccine 23, no. 17-18 (March 18, 2005): 2359–62. http://dx.doi.org/10.1016/j.vaccine.2005.01.082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Zhao, Lei, Jianjun Zhang, Liang Xu, and Hussein A. Abbas. "Novel Cancer Immunotherapies and Antitumor Immunity." Journal of Immunology Research 2019 (July 22, 2019): 1–2. http://dx.doi.org/10.1155/2019/3742061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Hoare, Joseph, Nicola Campbell, and Elisabete Carapuça. "Oncolytic virus immunotherapies in ovarian cancer." Porto Biomedical Journal 3, no. 1 (August 2018): e7. http://dx.doi.org/10.1016/j.pbj.0000000000000007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Davis, Laurie S. "Flora-ishing guts assist cancer immunotherapies." Science Immunology 3, no. 20 (February 2, 2018): eaat0813. http://dx.doi.org/10.1126/sciimmunol.aat0813.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Cancer immunotherapies' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography